Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
Arthur G. James Cancer Hospital - Ohio State University
mi
from
Columbus, OH
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
Arthur G. James Cancer Hospital - Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
U.S. Oncology Research, Inc.
mi
from
Dallas, TX
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
U.S. Oncology Research, Inc.
mi
from
Dallas, TX
Click here to add this to my saved trials
Comparison of Preoperative ABUS and MRI in Newly Diagnosed Breast Cancer Patients
Comparison of Preoperative Automated Breast Ultrasound (ABUS) and Magnetic Resonance Imaging (MRI) in Newly Diagnosed Breast Cancer Patients
Status: Enrolling
Updated:  1/18/2017
University of Kansas Cancer Center
mi
from
Westwood, KA
Comparison of Preoperative ABUS and MRI in Newly Diagnosed Breast Cancer Patients
Comparison of Preoperative Automated Breast Ultrasound (ABUS) and Magnetic Resonance Imaging (MRI) in Newly Diagnosed Breast Cancer Patients
Status: Enrolling
Updated: 1/18/2017
University of Kansas Cancer Center
mi
from
Westwood, KA
Click here to add this to my saved trials
Zinc Supplements in Lowering Cadmium Levels in Smokers
Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers?
Status: Enrolling
Updated:  1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Zinc Supplements in Lowering Cadmium Levels in Smokers
Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers?
Status: Enrolling
Updated: 1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
ZD-1839 (Iressa®) With Concurrent Docetaxel and Conformal Three Dimensional Thoracic Radiation Followed by Consolidative Docetaxel and ZD-1839 for Patients With Stage III Non Small Cell Lung Cancer: A Phase I Study
Status: Enrolling
Updated:  1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
ZD-1839 (Iressa®) With Concurrent Docetaxel and Conformal Three Dimensional Thoracic Radiation Followed by Consolidative Docetaxel and ZD-1839 for Patients With Stage III Non Small Cell Lung Cancer: A Phase I Study
Status: Enrolling
Updated: 1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Healing Touch in Treating Patients Receiving Chemotherapy for Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
Healing Touch as a Supportive Intervention for Adult Acute Leukemia Patients: A Pilot Study
Status: Enrolling
Updated:  1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Healing Touch in Treating Patients Receiving Chemotherapy for Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
Healing Touch as a Supportive Intervention for Adult Acute Leukemia Patients: A Pilot Study
Status: Enrolling
Updated: 1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases
Use of Music to Reduce Anxiety & Perceived Pain for Adult Patients With Hematological Malignancies Undergoing Bone Marrow Biopsy
Status: Enrolling
Updated:  1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases
Use of Music to Reduce Anxiety & Perceived Pain for Adult Patients With Hematological Malignancies Undergoing Bone Marrow Biopsy
Status: Enrolling
Updated: 1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer
Phase II Trial of Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative and HER-2 Negative Primary Breast Cancer
Status: Enrolling
Updated:  1/18/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer
Phase II Trial of Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative and HER-2 Negative Primary Breast Cancer
Status: Enrolling
Updated: 1/18/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer
Evaluation of a Yoga-Based Cancer Rehabilitation Program
Status: Enrolling
Updated:  1/23/2017
Albert Einstein College of Medicine
mi
from
Bronx, NY
Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer
Evaluation of a Yoga-Based Cancer Rehabilitation Program
Status: Enrolling
Updated: 1/23/2017
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Mind-Body Program for Cancer Patients
Evaluation of Mind-Body Groups on the Quality of Life of Cancer Patients
Status: Enrolling
Updated:  1/23/2017
Albert Einstein College of Medicine
mi
from
Bronx, NY
Mind-Body Program for Cancer Patients
Evaluation of Mind-Body Groups on the Quality of Life of Cancer Patients
Status: Enrolling
Updated: 1/23/2017
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer
A Phase II Trial of Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer Previously Treated With Docetaxel
Status: Enrolling
Updated:  1/23/2017
Weill-Cornell Medical College
mi
from
New York, NY
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer
A Phase II Trial of Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer Previously Treated With Docetaxel
Status: Enrolling
Updated: 1/23/2017
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Phase I Study of LB-100 With Docetaxel in Solid Tumors
A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/23/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Phase I Study of LB-100 With Docetaxel in Solid Tumors
A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/23/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Phase I Study of LB-100 With Docetaxel in Solid Tumors
A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/23/2017
The Mayo Clinic
mi
from
Rochester, MN
Phase I Study of LB-100 With Docetaxel in Solid Tumors
A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/23/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase I Study of LB-100 With Docetaxel in Solid Tumors
A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/23/2017
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Phase I Study of LB-100 With Docetaxel in Solid Tumors
A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/23/2017
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Phase I Study of LB-100 With Docetaxel in Solid Tumors
A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/23/2017
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Phase I Study of LB-100 With Docetaxel in Solid Tumors
A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/23/2017
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase I Study of LB-100 With Docetaxel in Solid Tumors
A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/23/2017
Texas Oncology-Tyler
mi
from
Tyler, TX
Phase I Study of LB-100 With Docetaxel in Solid Tumors
A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/23/2017
Texas Oncology-Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers
[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers
Status: Enrolling
Updated:  1/23/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers
[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers
Status: Enrolling
Updated: 1/23/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Englewood, CO
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Englewood, CO
Click here to add this to my saved trials
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Woodbury, MN
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Woodbury, MN
Click here to add this to my saved trials
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Rock Hill, NC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Rock Hill, NC
Click here to add this to my saved trials
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Tacoma, WA
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated:  1/23/2017
Clinical Research Facility
mi
from
Marietta, GA
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Status: Enrolling
Updated: 1/23/2017
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials
Identification of a Screening Tool and Treatment of Lymphedema Secondary to the Management of Breast Cancer Study
Identification of a Screening Tool and Treatment of Lymphedema Secondary to the Management of Breast Cancer Study
Status: Enrolling
Updated:  1/23/2017
Avon Breasts Center, Johns Hopkins Medical Institutions
mi
from
Baltimore, MD
Identification of a Screening Tool and Treatment of Lymphedema Secondary to the Management of Breast Cancer Study
Identification of a Screening Tool and Treatment of Lymphedema Secondary to the Management of Breast Cancer Study
Status: Enrolling
Updated: 1/23/2017
Avon Breasts Center, Johns Hopkins Medical Institutions
mi
from
Baltimore, MD
Click here to add this to my saved trials
Health Interventions in Men Undergoing Radical Prostatectomy
Health Interventions in Men Undergoing Radical Prostatectomy- A Randomized Controlled Clinical Trial
Status: Enrolling
Updated:  1/25/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Health Interventions in Men Undergoing Radical Prostatectomy
Health Interventions in Men Undergoing Radical Prostatectomy- A Randomized Controlled Clinical Trial
Status: Enrolling
Updated: 1/25/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Navigation From Community to Clinic to Promote CRC Screening in Underserved Populations
Navigation From Community to Clinic to Promote CRC Screening in Underserved Populations
Status: Enrolling
Updated:  1/25/2017
Arizona State University
mi
from
Phoenix, AZ
Navigation From Community to Clinic to Promote CRC Screening in Underserved Populations
Navigation From Community to Clinic to Promote CRC Screening in Underserved Populations
Status: Enrolling
Updated: 1/25/2017
Arizona State University
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Evaluating the Effectiveness of Art Therapy on Mood, Anxiety, and Pain Levels in Cancer Patients
Evaluating the Effectiveness of Art Therapy on Mood, Anxiety, and Pain Levels in Cancer Patients Undergoing Chemotherapy Treatment
Status: Enrolling
Updated:  1/25/2017
Maroone Cancer Center - Cleveland Clinic Florida
mi
from
Weston, FL
Evaluating the Effectiveness of Art Therapy on Mood, Anxiety, and Pain Levels in Cancer Patients
Evaluating the Effectiveness of Art Therapy on Mood, Anxiety, and Pain Levels in Cancer Patients Undergoing Chemotherapy Treatment
Status: Enrolling
Updated: 1/25/2017
Maroone Cancer Center - Cleveland Clinic Florida
mi
from
Weston, FL
Click here to add this to my saved trials
Endocytoscopy and Colorectal Neoplasia
The Role of in Vivo Real Time Endocytoscopy in Diagnosing Colorectal Neoplasia
Status: Enrolling
Updated:  1/25/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Endocytoscopy and Colorectal Neoplasia
The Role of in Vivo Real Time Endocytoscopy in Diagnosing Colorectal Neoplasia
Status: Enrolling
Updated: 1/25/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
Phase I/II Study of Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/26/2017
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
Phase I/II Study of Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/26/2017
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated:  1/27/2017
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated: 1/27/2017
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated:  1/27/2017
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated: 1/27/2017
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Click here to add this to my saved trials
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated:  1/27/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated: 1/27/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated:  1/27/2017
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated: 1/27/2017
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated:  1/27/2017
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated: 1/27/2017
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated:  1/27/2017
Memorial Sloan Kettering West Harrison
mi
from
West Harrison, NY
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
Status: Enrolling
Updated: 1/27/2017
Memorial Sloan Kettering West Harrison
mi
from
West Harrison, NY
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Northwest Alabama Cancer Center
mi
from
Florence, AL
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Northwest Alabama Cancer Center
mi
from
Florence, AL
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Highlands Oncology Group
mi
from
Bentonville, AR
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Highlands Oncology Group
mi
from
Bentonville, AR
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Pacific Medical Center
mi
from
Anaheim, CA
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Pacific Medical Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Providence St. Joseph Medical Center
mi
from
Burbank, CA
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Providence St. Joseph Medical Center
mi
from
Burbank, CA
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Kenmar Research Institute
mi
from
Los Angeles, CA
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Kenmar Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
AMPM Research Clinic
mi
from
Miami Gardens, FL
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
AMPM Research Clinic
mi
from
Miami Gardens, FL
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Illinois Cancer Specialists
mi
from
Niles, IL
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Illinois Cancer Specialists
mi
from
Niles, IL
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Indiana University Cancer Center
mi
from
Beech Grove, IN
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Indiana University Cancer Center
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
University of Louisville James Brown Cancer Center
mi
from
Louisville, KY
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
University of Louisville James Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated:  1/30/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Status: Enrolling
Updated: 1/30/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials